** Omnicell's OMCL.O shares down 7% at $42.81 Tues as medical software co seeks capital raise
** Fort Worth, Texas-based firm early Tues said offering privately $150 mln 5-yr convertible bonds (CBs)
** Co expects to use portion of net proceeds to pay for capped calls, remainder, along with cash, to repurchase up to $400 mln of its outstanding 0.25% CBs due 2025
** On Oct 29, shares soared 32% to close at $53.05 after co posted big adj Q3 EPS beat and hiked its FY 2024 earnings outlook
** With move on Tues, shares up 14% YTD for market value of ~$2 bln, per LSEG
** Of 9 analysts covering OMCL, 3 rate "buy", rest "hold"; median PT of $60 up from $44.50 a month ago
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper.thomsonreuters.com@reuters.net lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.